Treatment of Adenoviral Conjunctivitis With SHP640 Compared to Placebo

NCT ID: NCT02998554

Last Updated: 2021-06-09

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE3
• Total Enrollment: 156 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2017-03-28
• Study Completion Date: 2019-05-16

Brief Summary

The purpose of this study is to determine if an investigational treatment is effective compared with placebo in the treatment of adults and children with adenoviral conjunctivitis.

Conditions

Adenoviral Conjunctivitis

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

SHP640

Participants instructed to instill 1 drop of SHP640 (Povidone-iodine \[PVP-I\] 0.6 percent \[%\] and Dexamethasone 0.1%) ophthalmic suspension in each eye 4 times daily (QID) (with a minimum of 2 hours between doses) for 7 days.

Group Type: EXPERIMENTAL

SHP640

Intervention Type: DRUG

Instill 1 drop of SHP640 (PVP-I 0.6% and Dexamethasone 0.1%) ophthalmic suspension in each eye 4 times daily (QID) (with a minimum of 2 hours between doses) for 7 days.

Placebo

Participants instructed to instill 1 drop of placebo ophthalmic solution in each eye QID for 7 days.

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Instill 1 drop of placebo ophthalmic solution in each eye QID for 7 days.

Interventions

SHP640

Instill 1 drop of SHP640 (PVP-I 0.6% and Dexamethasone 0.1%) ophthalmic suspension in each eye 4 times daily (QID) (with a minimum of 2 hours between doses) for 7 days.

Intervention Type: DRUG

Placebo

Instill 1 drop of placebo ophthalmic solution in each eye QID for 7 days.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. An understanding, ability, and willingness to fully comply with study procedures and restrictions (by the parent(s), guardian, or legally authorized representative, if applicable).

2. Ability to voluntarily provide written, signed, and dated (personally or via a parent(s), guardian, or legally-authorized representative(s) informed consent (and assent, if applicable) to participate in the study.

3. Participants of any age at Visit 1 (Note: Participants less than (<) 3 months of age at Visit 1 must have been full-term, that is greater than or equal to (>=) 37 weeks gestational age at birth).

4. Meet at least 1 of the 2 criteria below: a. Have a positive AdenoPlus® test at Visit 1 in at least 1 eye; b. Have at least 2 of the following 5 criteria, based upon medical history and examination: i. Symptoms within the past 7 days consistent with acute upper respiratory tract infection (example: sore throat, cough, rhinorrhea, etc); ii. Contact within the past 7 days with family members or other individuals with recent onset of symptoms consistent with conjunctivitis; iii. Acute onset within the past 4 days of 1 or more of the following ocular symptoms: burning/irritation, foreign body sensation, light sensitivity; iv. Enlarged periauricular lymph node(s); v. Presence of follicles on tarsal conjunctiva.

Note: If the participant only meets Inclusion Criterion 4a (a positive AdenoPlus test in at least 1 eye), then the same eye must meet Inclusion Criterion 5.

5. Have a clinical diagnosis of suspected adenoviral conjunctivitis in at least 1 eye confirmed by the presence of the following minimal clinical signs and symptoms in that same eye: Report presence of signs and/or symptoms of adenoviral conjunctivitis for less than or equal to (<=) 4 days prior to Visit 1; Bulbar conjunctival injection: a grade of >=1 on 0-4 scale of Bulbar Conjunctival Injection Scale; Watery conjunctival discharge: a grade of >=1 (mild) on a 0-3 Watery Conjunctival Discharge Scale.

6. Be willing to discontinue contact lens wear for the duration of the study.

7. Have a Best Corrected Visual Acuity (BCVA) of 0.60 logMAR or better in each eye as measured using an Early Treatment Diabetic Retinopathy Study (ETDRS) chart. BCVA will be assessed by an age appropriate method in accordance with the American Academy of Pediatrics (AAP) Policy Statement for Visual System Assessment in Infants, Children, and Young Adults by Pediatricians. The policy statement recommends formal vision screening can begin at 3 years of age. VA measurements for children under the age of 3 will be done at the discretion of the investigator. If not done, child should be able to fixate on and follow a moving object, except participants < 2 months of age who have not yet developed this ability. Participants < 2 months will be enrolled at the discretion of the investigator.

8. Male, or non-pregnant, non-lactating female who agrees to comply with any applicable contraceptive requirements of the protocol or females of non-childbearing potential.

Exclusion Criteria

1. Current or recurrent disease that could affect the action, absorption, or disposition of the investigational product, or clinical or laboratory assessments, per investigator's discretion.

2. Current or relevant history of physical or psychiatric illness, any medical disorder that may make the participant unlikely to fully complete the study, or any condition that presents undue risk from the investigational product or procedures.

3. Have known or suspected intolerance or hypersensitivity to the investigational product, closely related compounds, or any of the stated ingredients.

4. Prior enrollment in a FST-100 or SHP640 clinical study.

5. Participants who are employees, or immediate family members of employees (who are directly related to study conduct), at the investigational site.

6. Have a history of ocular surgical intervention within <= 6 months prior to Visit 1 or planned for the period of the study.

7. Have a preplanned overnight hospitalization during the period of the study.

8. Have presence of any intraocular, corneal, or conjunctival ocular inflammation (example: uveitis, iritis, ulcerative keratitis, chronic blepharoconjunctivitis), other than adenoviral conjunctivitis.

9. Have presence of corneal subepithelial infiltrates at Visit 1.

10. Have active or history of ocular herpes.

11. Have at enrollment or within <= 30 days of Visit 1, a clinical presentation more consistent with the diagnosis of non-infectious conjunctivitis (except presumed seasonal/perennial allergic conjunctivitis) or non-adenoviral ocular infection (example: bacterial, fungal, acanthamoebal, or other parasitic).

Note: History or concomitant presence of presumed seasonal or perennial allergic conjunctivitis signs/symptoms is not exclusionary.

12. Neonates or infants (that is (ie,) participants < 12 months of age) who have suspected or confirmed (based on the result of any test conducted prior to screening) conjunctivitis of gonococcal, chlamydial, herpetic or chemical origin.

13. Neonates or infants (ie, participants < 12 months of age) whose birth mothers had any sexually transmitted disease within 1 month of delivery or any history of genital herpes.

14. Presence of nasolacrimal duct obstruction at Visit 1 (Day 1).

15. Presence of any significant ophthalmic condition (example: retinopathy of prematurity, congenital cataract, congenital glaucoma) or other congenital disorder with ophthalmic involvement that could affect study variables.

16. Be a known intraocular pressure (IOP) steroid responder, have a known history or current diagnosis of glaucoma, or be a glaucoma suspect.

17. Have any known clinically significant optic nerve defects.

18. Have a history of recurrent corneal erosion syndrome, either idiopathic or secondary to previous corneal trauma or dry eye syndrome; presence of corneal epithelial defect or any significant corneal opacity at Visit 1.

19. Presence of significant, active condition in the posterior segment which requires invasive treatment (example: intravitreal treatment with VEGF inhibitors or corticosteroids) and may progress during the study participation period.

20. Have used any topical ocular or systemic anti-virals or antibiotics within <= 7 days of enrollment.

21. Have used any topical ocular NSAIDs within <= 1 day of enrollment.

22. Have used any topical ophthalmic steroids in the last <= 14 days.

23. Have used any systemic corticosteroid agents within <= 14 days of Day 1. Stable (initiated >= 30 days prior to enrollment) use of inhaled and nasal corticosteroids is allowed, given no anticipated change in dose for the duration of the study. Topical dermal steroids are allowed except in the peri-ocular area.

24. Have used non-corticosteroid immunosuppressive agents within <= 14 days of Day 1.

25. Have used any topical ophthalmic products, including tear substitutes, and over-the-counter preparations such as lid scrubs, within 2 hours of Visit 1 and be unable to discontinue all topical ophthalmic products for the duration of the study. Use of hot or cold compresses is also not permitted during the study.

26. Have any significant ocular disease (example: Sjogren's syndrome) or any uncontrolled systemic disease or debilitating disease (example: cardiovascular disease, hypertension, sexually transmitted diseases/infections, diabetes or cystic fibrosis), that may affect the study parameters, per investigator's discretion.

27. Any known history of immunodeficiency disorder or known active conditions predisposing to immunodeficiency, such as human immunodeficiency virus, hepatitis B or C, evidence of active hepatitis A (antihepatitis A virus immunoglobulin M), or organ or bone marrow transplantation.

28. Within 30 days prior to the first dose of investigational product: Have used an investigational product or device, or Have been enrolled in a clinical study (including vaccine studies) that, in the investigator's opinion, may impact this Shire-sponsored study.

• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Shire

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Study Director

Role: STUDY_DIRECTOR

Takeda

Locations

Lugene Eye Institute Inc

Glendale, California, United States

University of Southern California

Los Angeles, California, United States

Wolstan and Goldberg Eye Associates

Torrance, California, United States

Danbury Eye Physicians and Surgeons

Danbury, Connecticut, United States

Bruce A. Segal, MD, PA

Delray Beach, Florida, United States

Bowden Eye & Associates

Jacksonville, Florida, United States

Shettle Eye Research, Inc.

Largo, Florida, United States

South Florida Research Center Inc.

Miami, Florida, United States

International Research Center

Tampa, Florida, United States

Saltzer Medical Group

Nampa, Idaho, United States

Sabates Eye Centers

Leawood, Kansas, United States

Physicians to Children & Adolescents

Bardstown, Kentucky, United States

The Eye Care Institute

Louisville, Kentucky, United States

Shire Call Center

Lexington, Massachusetts, United States

Silverstein Eye Centers

Kansas City, Missouri, United States

Washington University

St Louis, Missouri, United States

Tekwani Vision Center

St Louis, Missouri, United States

Wellish Vision Institute

Las Vegas, Nevada, United States

Fichte, Endl and Elmer Eyecare

Niagara Falls, New York, United States

Apex Eye Kenwood

Cincinnati, Ohio, United States

Cleveland Eye Clinic

Cleveland, Ohio, United States

The Ohio State University

Columbus, Ohio, United States

IPS Research Company

Oklahoma City, Oklahoma, United States

Eyeland Vision

El Paso, Texas, United States

Houston Eye Associates

Houston, Texas, United States

Sun Research Institute, LLC

San Antonio, Texas, United States

Jean Brown Research

Salt Lake City, Utah, United States

Chrysalis Clinical Research

St. George, Utah, United States

Piedmont Eye Center, Inc.

Lynchburg, Virginia, United States

Emanuelli Research & Development Center, LLC

Arecibo, , Puerto Rico

University Of Puerto Rico, School of Medicine

Carolina, , Puerto Rico

Countries

United States; Puerto Rico

Provided Documents

Document Type: Study Protocol: Protocol

View Document

Document Type: Study Protocol: Amendment 1

View Document

Document Type: Study Protocol: Amendment 2

View Document

Document Type: Study Protocol: Amendment 3

View Document

Document Type: Study Protocol: Amendment 4

View Document

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

2016-002440-16

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

SHP640-302

Identifier Type: -

Identifier Source: org_study_id